Clinical Trials Browser

Disease Progression × brigatinib × Clear all

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression